Idogen’s investor events in October-November 2019

During October and November 2019, Idogen AB's ("Idogen") CEO Anders Karlsson will present the company at several investor events. New and future shareholders are warmly welcomed to the events. For more information, see below.

BioStock Life Science Summit in Lund, October 23
Date: Wednesday October 23 2019, time will be announced later
Location: Medicon Village, Scheelevägen 2, Lund
Organizer: BioStock, for more information and participation, please visit: summit.biostock.se

Stora aktiedagen Gothenburg, November 4
Date: Monday November 4 2019, time will be announced later 
Location: Svenska Mässan, Mässans gata 24, Göteborg 
Organizer: Aktiespararna, for more information and participation, please visit: aktiespararna.se/evenemang

Redeye Life Science Day in Stockholm, November 19
Date: Tuesday November 19 2019, time will be announced later
Location: Haymarket by Scandic, Hötorget, Stockholm 
Organizer: Redeye, for more information and participation, please visit: redeye.se 

Stora aktiedagen Stockholm, November 25
Date: Monday November 25 2019, time will be announced later
Location: Hotel Sheraton, Tegelbacken 6, Stockholm
Organizer: Aktiespararna, for more information and participation, please visit: aktiespararna.se/evenemang

For additional information, please contact:
Anders Karlsson, CEO Idogen AB
Phone: +46 (0) 709 18 00 10
Email: anders.karlsson@idogen.com   

Idogen (Spotlight Stock Market: IDOGEN) utvecklar cellterapier för att undvika att biologiska läkemedel, transplanterade organ eller kroppens egen vävnad angrips av patientens immunförsvar. Bolagets längst framskridna projekt IDO 8 syftar till att återställa effekten av läkemedel mot blödarsjuka hos patienter som utvecklat hämmande antikroppar. Bolagets andra projekt IDO T utvecklas för att förhindra avstötning av transplanterade njurar. I ett tredje projekt, IDO AID, inriktar sig Idogen på behandling av autoimmuna sjukdomar. Behandlingen baseras på patientens egna celler och förväntas ha en gynnsam säkerhetsprofil och långvarig effekt. Att en kort behandling har potential att ge en mycket långvarig effekt är ytterligare en stor fördel. För mer information, besök www.idogen.com

Tags:

About Us

Idogen AB (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. Idogen’s intention is to revolutionize the treatment of several disorders in which the body’s immune system does not function as it should, and for which there is a major unmet medical need – such as in autoimmune diseases, organ transplant rejection and in patients who have developed anti-drug antibodies.

Subscribe

Media

Media